1.Global tuberculosis report 2018: World Health Organization; 2019.
2.Seung KJ, Salmaan K, Rich ML: Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harbor Perspectives in Medicine 2015, 5(9):a017863.
3.Falzon D,., Jaramillo E,., Schünemann HJ, Arentz M,., Bauer M,., Bayona J,., Blanc L,., Caminero JA, Daley CL, Duncombe C,. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. 2011, 38(3):516–528.
4.Duggar BM: Aureomycin: a product of the continuing search for new antibiotics. Annals of the New York Academy of Sciences 1948, 51(2):177–181.
5.FINLAY AC, Hobby G, P’an S, Regna P, Routien J, Seeley D, Shull G, Sobin B, Solomons I, Kane J: Terramycin, a new antibiotic. Science (Washington) 1950:85–87.
6.KING EQ, LEWIS CN, WELCH H, CLARK EA, JOHNSON JB, LYONS JB, SCOTT RB, CORNELY PB: Clinical observations on the use of Terramycin hydrochloride. Journal of the American Medical Association 1950, 143(1):1–4.
7.Roberts MC: Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS microbiology reviews 1996, 19(1):1–24.
8.Nelson ML, Levy SB: The history of the tetracyclines. Annals of the New York Academy of Sciences 2011, 1241(1):17–32.
9.Sum PE, Lee VJ, Testa RT, Hlavka JJ, Ellestad GA, Bloom JD, Gluzman Y,., Tally FP: Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. Journal of Medicinal Chemistry 1994, 37(1):184.
10.Klein NC, Cunha BA: Tetracyclines. Medical Clinics of North America 1995, 79(4):789–801.
11.Brodersen DE, Clemons Jr WM, Carter AP, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V: The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 2000, 103(7):1143–1154.
12.Wilson DN: The A–Z of bacterial translation inhibitors. Critical reviews in biochemistry and molecular biology 2009, 44(6):393–433.
13.Griffin MO, Fricovsky E, Ceballos G, Villarreal F: Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. American Journal of Physiology-Cell Physiology 2010, 299(3):C539-C548.
14.Walker NF, Clark SO, Tolu O, Nuria A, Liku T, Shivani S, Luísa S, Bernadette P, Kelly DL, Tree JA: Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. American Journal of Respiratory & Critical Care Medicine 2012, 185(9):989–997.
15.Balabanova Y, Ruddy M, Hubb J, Yates M, Malomanova N, Fedorin I, Drobniewski F: Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy. European Journal of Clinical Microbiology and Infectious Diseases 2005, 24(2):136–139.
16.Gonzalo X, Casali N, Broda A, Pardieu C, Drobniewski F: Combination of amikacin and doxycycline against multidrug-resistant and extensively drug-resistant tuberculosis. International Journal of Antimicrobial Agents 2015, 45(4):406–412.
17.Hobby GL, Lenert TF: Antituberculous activity of tetracycline and related compounds. American Review of Tuberculosis and Pulmonary Diseases 1955, 72(3):367–372.
18.Irith W, Kai H, Hancock REW: Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nature Protocols 2008, 3(2):163–175.
19.Sassetti CM, Boyd DH, Rubin EJ: Comprehensive identification of conditionally essential genes in mycobacteria. Proceedings of the National Academy of Sciences 2001, 98(22):12712–12717.
20.Guilhot C, Otal I, Van Rompaey I, Martin C, Gicquel B: Efficient transposition in mycobacteria: construction of Mycobacterium smegmatis insertional mutant libraries. Journal of bacteriology 1994, 176(2):535–539.
21.Parish T, Brown AC: Mycobacteria protocols: Springer; 2008.
22.Paul C, Muttucumaru DGN, Tanya P: Use of a tetracycline-inducible system for conditional expression in Mycobacterium tuberculosis and Mycobacterium smegmatis. Applied & Environmental Microbiology 2005, 71(6):3077–3084.
23.Coban AY, Deveci A, Cayci YT, Uzun M, Akgunes A, Durupinar B: In vitro effect of tigecycline against Mycobacterium tuberculosis and a review of the available drugs for tuberculosis. African Journal of Microbiology Research 2011, 5(3):311–315.
24.Agwuh KN, MacGowan A: Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. Journal of Antimicrobial Chemotherapy 2006, 58(2):256–265.
25.Newton PN, Chaulet J-F, Brockman A, Chierakul W, Dondorp A, Ruangveerayuth R, Looareesuwan S, Mounier C, White NJ: Pharmacokinetics of oral doxycycline during combination treatment of severe falciparum malaria. Antimicrobial agents and chemotherapy 2005, 49(4):1622–1625.
26.Newton GL, Ta P, Bzymek KP, Fahey RC: Biochemistry of the initial steps of mycothiol biosynthesis. Journal of Biological Chemistry 2006, 281(45):33910–33920.
27.Vilcheze C, Av-Gay Y, Barnes SW, Larsen MH, Walker JR, Glynne RJ, Jacobs WR: Coresistance to Isoniazid and Ethionamide Maps to Mycothiol Biosynthetic Genes in Mycobacterium bovis. Antimicrobial Agents and Chemotherapy 2011, 55(9):4422–4423.
28.Xia X, Catherine V, Yossef AG, Anaximandro GV, Jacobs WR: Precise null deletion mutations of the mycothiol synthesis genes reveal their role in isoniazid and ethionamide resistance in Mycobacterium smegmatis. Antimicrobial Agents & Chemotherapy 2011, 55(7):3133–3139.
29.Vilchèze C, Av‐Gay Y, Attarian R, Liu Z, Hazbón MH, Colangeli R, Chen B, Liu W, Alland D, Sacchettini JC: Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis. Molecular microbiology 2008, 69(5):1316–1329.
30.Michael F, Michael N, Schulz GE: The structure of a mycobacterial outer-membrane channel. Science 2004, 303(5661):1189–1192.
31.Joachim S, Claudia M, Gilles E, Mamadou D, Michael N: Multidrug resistance of a porin deletion mutant of Mycobacterium smegmatis. Antimicrobial Agents & Chemotherapy 2004, 48(11):4163.
32.Danilchanka O, Pavlenok M, M: Role of porins for uptake of antibiotics by Mycobacterium smegmatis. Antimicrobial Agents & Chemotherapy 2008, 52(9):3127.
33.Frenzel E, Schmidt S, Niederweis M, Steinhauer K: Importance of Porins for Biocide Efficacy against Mycobacterium smegmatis. Applied and Environmental Microbiology.
34.Dietmar H, Iris E, Anja T, Michael N: Expression of the major porin gene mspA is regulated in Mycobacterium smegmatis. Journal of Bacteriology 2007, 189(3):958.
35.Pavlenok M, Niederweis M: Hetero-oligomeric MspA pores in Mycobacterium smegmatis. Fems Microbiology Letters 2016, 363(7):fnw046.
36.Njire M, Tan Y, Mugweru J, Wang C, Guo J, Yew W, Tan S, Zhang T: Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update. Advances in medical sciences 2016, 61(1):63–71.
37.Rubinstein E, Vaughan D: Tigecycline. Drugs 2005, 65(10):1317–1336.
38.Wallace RJ, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW: Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR–936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrobial Agents and Chemotherapy 2002, 46(10):3164–3167.
39.Joshi N, Miller DQ: Doxycycline Revisited. JAMA Internal Medicine 1997, 157(13):1421–1428.
40.Sarkar S, Thach RE: Inhibition of formylmethionyl-transfer RNA binding to ribosomes by tetracycline. Proceedings of the National Academy of Sciences of the United States of America 1968, 60(4):1479.
41.Janin YL: Antituberculosis drugs: ten years of research. Bioorganic & medicinal chemistry 2007, 15(7):2479–2513.
42.Arbex MA, Varella MdCL, Siqueira HRd, Mello FAFd: Antituberculosis drugs: drug interactions, adverse effects, and use in special situations-part 1: first-line drugs. Jornal Brasileiro de Pneumologia 2010, 36(5):626–640.
43.Mortimer PG, Piddok LJ: The accumulation of five antibacterial agents in porin-deficient mutants of Escherichia coli. Journal of Antimicrobial Chemotherapy 1993, 32(2):195–213.
44.Thanassi DG, Suh G, Nikaido H: Role of outer membrane barrier in efflux-mediated tetracycline resistance of Escherichia coli. Journal of bacteriology 1995, 177(4):998–1007.
45.Pugsley AP, Schnaitman CA: Outer membrane proteins of Escherichia coli VII. Evidence that bacteriophage-directed protein 2 functions as a pore. Journal of bacteriology 1978, 133(3):1181–1189.
46.Trieber CA, Taylor DE: Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. Journal of bacteriology 2002, 184(8):2131–2140.
47.Buchmeier NA, Newton GL, Fahey RC: A mycothiol synthase mutant of Mycobacterium tuberculosis has an altered thiol-disulfide content and limited tolerance to stress. Journal of bacteriology 2006, 188(17):6245–6252.